Michael Sapienza: New Study by Emil Lou Underscores the Critical Need for More Colorectal Cancer Research
Michael Sapienza, Chief Executive Officer at Colorectal Cancer Alliance, shared on LinkedIn:
“A recent study published in The Lancet Group underscores the critical need for more colorectal cancer research to improve treatments and survival rates.
The study conducted by Emil Lou used immune cells from patients’ tumors to devise a designer type of treatment – customized for each individual patient in the trial.
Half of the patients with colorectal cancer had stable disease one month after treatment, and one young adult patient with Stage IV colon cancer previously resistant to multiple forms of chemotherapy and immunotherapy, completely responded to the treatment and remains cancer-free more than two years later.
We must continue to push for more innovative research to make progress and end this disease in our lifetime. To help us fund Project Cure CRC research visit.
Read the full study here.
Learn about the patient’s story here.”
Title: Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial
Authors: Emil Lou, Modassir S Choudhry, Timothy K Starr, Timothy D Folsom, Jason Bell, Blaine Rathmann, Anthony P DeFeo, Jihyun Kim, Nicholas Slipek, Zhaohui Jin, Darin Sumstad, Christopher A Klebanoff, Katherine Ladner, Akshat Sarkari, R Scott McIvor, Thomas A Murray, Jeffrey S Miller, Madhuri Rao, Eric Jensen, Jacob Ankeny, Mahmoud A Khalifa, Anil Chauhan, Benjamin Spilseth, Ajay Dixit, Paolo P Provenzano, Wenjing Pan, Daniel Weber, Miranda Byrne-Steele, Tom Henley, David H McKenna, Matthew J Johnson, Beau R Webber, Branden S Moriarity
Read Full Article on The Lancet Oncology.
More posts featuring Michael Sapienza.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023